img slider
Have you or a loved one taken Risperdal and experienced complications such as male breast growth or nipple discharge?

Billions Recovered

Since 1993, Bernstein Liebhard has collected more than $3 billion dollars fighting for injured consumers and shareholders.
Learn more

National Represenation

From our offices in New York, we handle Risperdal and Invega lawsuits nationwide. We work with Plaintiffs from all 50 states.
Learn more

No Recovery, No Fee 

We accept cases on a contingency fee basis. No legal fees are owed unless we make a monetary recovery on your behalf.
Learn more

What’s my case worth?

Have you suffered side effects caused by Risperdal? Find out what type of compensation you might be eligible to receive.
Learn more

Have Any Risperdal Lawsuit Settlements Been Reached?

A number of Risperdal lawsuit settlements reported in recent months have brought more attention to the litigation surrounding the drug, especially claims that allege a connection between Risperdal and gynecomastia (male breast growth). While the majority of these claims remain unresolved, cases are moving forward quickly. If you or a loved one experienced male breast growth that could be associated with Risperdal, it is vital that you seek legal advice immediately, as you may be entitled to compensation for your injury-related damages, including emotional distress. The attorneys at Bernstein Liebhard LLP are offering free case reviews to alleged victims of Risperdal gynecomastia. To learn if you might qualify to file a claim, please contact our office today, by calling (855) 511-1001.

Justice Department Announces Risperdal Settlement with Johnson & Johnson

The most notable lawsuit settlement was announced in November 2013 by the U.S. Department of Justice. That month, Johnson & Johnson agreed to pay $2.2 billion to settle a case with the federal government regarding the marketing of Risperdal and other medications sold by its Janssen Pharmaceuticals unit. Neither company admitted to any wrongdoing in settling civil charges brought by federal prosecutors regarding the alleged marketed the antipsychotic for use in children. However, they did plead guilty to a misdemeanor criminal charge of improperly marketing the drug as a treatment for elderly dementia patients. The $2.2 billion settlement included criminal fines and forfeiture of $485 million, as well as $1.72 billion in civil penalties, and also resolved similar accusations brought by 45 states, according to a The New York Times report. The civil charges allege that Risperdal was marketed for use in children well before the drug received agency approval for pediatric treatment in 2006 and that Johnson & Johnson was aware that Risperdal posed significant risks to pediatric patients, including a risk of gynecomastia. In announcing this settlement, U.S. Attorney General Eric Holder said that Johnson & Johnson had “recklessly put at risk the health of some of the most vulnerable members of our society—including young children, the elderly and the disabled.”

Risperdal Settlements Reached in Gynecomastia Injury Cases

Last year, Johnson & Johnson also agreed to five settlements over claims that its antipsychotic medication increased breast-tissue growth in boys, according to a Bloomberg News report. The terms of the settlements have not been released, but cover cases that were scheduled to be tried in Philadelphia, Pennsylvania. The drug maker denies any wrongdoing. All of the settled cases had been pending in a consolidated litigation underway Philadelphia Common Pleas Court, where Johnson & Johnson and Janssen are named as defendants in more than 200 lawsuits that allege use of the antipsychotic drug caused a variety of serious side effects, including male breast growth. One of the plaintiff’s attorneys told Bloomberg News that Johnson & Johnson hid Risperdal’s ties to increased hormone levels that lead to breast development in males. The drug maker also trained its sales staff to minimize adverse event information when speaking to physicians, according to the attorney. Johnson & Johnson’s attorneys argue that the boy’s breast development was a normal part of puberty, denying that the drug maker illegally marketed Risperdal. In November 2013, some 77 plaintiffs who currently have gynecomastia claims pending in the Pennsylvania litigation filed a motion seeking to have Risperdal settlements enforced that they say were reached with Johnson & Johnson earlier this year. According to plaintiffs, the company threatened to back out of the agreements if they were not expanded to include claims filed against specific third-party defendants. The plaintiffs allege that Johnson & Johnson has always known that this stipulation was never part of the Risperdal settlements, and that the company only just very recently raised this issue.

Learn More About Risperdal Settlements

If you or someone you care about took this medication and developed gynecomastia, and you would like to learn more about recent Risperdal lawsuit settlements and the ongoing litigation involving this drug, Bernstein Liebhard LLP can help. To contact one of our attorneys for a free, no-obligation case review, please call (855) 511-1001.